Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 165

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

Corey, G. R., Wilcox, M. H., Talbot, G. H., Thye, D., Friedland, D., Baculik, T., on behalf of the CANVAS 1 investigators, Mehra, P., Alpert, M., Baird, I., Klein, S., Litow, J., Marsh, P., Penn, R., Augustinsk, J., Young, D., Bunce, C., Green, D., Eyzaguirre, R., Ambasch, G., Curcio, D. J., Lopardo, G., Minguez, A. R., Oliva, M. E., Teglia, O. F., Campos, M., Gaete, P., Acuna, G., Jansen, L., Jauregui, A., Perez, C., Seas, C., Gutierrez, J., Mayorga, M., Bubnova, N. A., Goryunov, S. V., Krylov, K. M., Macheret, E. A., Novozhilov, A. A., Zhidkov, K. P., Kozlov, R. S., Florescu, I. P., Orasan, R., Trifu, V., Ockenfels, H.-M., Hermes, B., Brockmeyer, N., Dippel, E., Kujath, P., Kowalzick, L., Ulrich, J., Krasnodebski, I., Jaworski, R., Zaniewski, M., Wallner, G., Kapinska-Mrowiecka, M., Dziki, A., Motyka, M., Borschivsky, V. M., Gerych, I. D., Lukashov, S. M., Pyptyuk, O. V. · 2010 · Journal of Antimicrobial Chemotherapy

Abstract

OBJECTIVES: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a common cause of complicated skin and skin structure infections (cSSSIs). Increasing antibiotic resistance and significant morbidity in cSSSIs have led to a need for new effective and safe therapies. Ceftaroline fosamil, a novel parenteral cephalosporin with excellent in vitro activity against Gram-positive pathogens, including MRSA, and many Gram-negative pathogens, was evaluated as therapy for cSSSIs in a large multicentre study. The primary study objective was to determine non-inferiority [lower limit of 95% confidence interval (CI), -10%] in the clinical cure rate achieved with ceftaroline fosamil monotherapy compared with that achieved with vancomycin plus aztreonam in the clinically evaluable (CE) and modified intent-to-treat (MITT) patient populations. METHODS: Adult patients with cSSSIs requiring intravenous therapy received 600 mg of ceftaroline fosamil every 12 h or 1 g of vancomycin plus 1 g of aztreonam every 12 h for 5-14 days (randomized 1 : 1). Clinical and microbiological response, adverse events (AEs) and laboratory tests were assessed. Registration number NCT00424190 (http://clinicaltrials.gov/ct2/show/NCT00424190). RESULTS: Of 702 enrolled patients, 353 received ceftaroline fosamil and 349 received vancomycin plus aztreonam. Baseline characteristics of treatment groups were comparable. Clinical cure rates were similar for ceftaroline fosamil and vancomycin plus aztreonam in the CE (91.1%, 288/316 versus 93.3%, 280/300; 95% CI, -6.6, 2.1) and MITT (86.6%, 304/351 versus 85.6%, 297/347; 95% CI, -4.2, 6.2) populations, respectively. The clinical cure rate for MRSA cSSSIs was 95.1% (78/82) for ceftaroline fosamil and 95.2% (59/62) for vancomycin plus aztreonam. The microbiological success rate was also similar for ceftaroline fosamil and vancomycin overall, and for MRSA. The rates of AEs, serious AEs, deaths and discontinuations because of an AE were similar for ceftaroline fosamil and vancomycin plus aztreonam. The most common AEs for ceftaroline fosamil and vancomycin plus aztreonam were diarrhoea (3.4% versus 3.2%), nausea (5.7% versus 4.6%), headache (5.1% versus 3.7%) and pruritus (3.1% versus 8.4%), respectively. CONCLUSIONS: Ceftaroline fosamil achieved high clinical cure and microbiological success rates, was efficacious for cSSSIs caused by MRSA and other common cSSSI pathogens and was generally well tolerated. Ceftaroline fosamil has the potential to provide a monotherapy alternative for treatment of cSSSIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/dkq254

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 165

Metadata

Authors
Corey, G. R., Wilcox, M. H., Talbot, G. H., Thye, D., Friedland, D., Baculik, T., on behalf of the CANVAS 1 investigators, Mehra, P., Alpert, M., Baird, I., Klein, S., Litow, J., Marsh, P., Penn, R., Augustinsk, J., Young, D., Bunce, C., Green, D., Eyzaguirre, R., Ambasch, G., Curcio, D. J., Lopardo, G., Minguez, A. R., Oliva, M. E., Teglia, O. F., Campos, M., Gaete, P., Acuna, G., Jansen, L., Jauregui, A., Perez, C., Seas, C., Gutierrez, J., Mayorga, M., Bubnova, N. A., Goryunov, S. V., Krylov, K. M., Macheret, E. A., Novozhilov, A. A., Zhidkov, K. P., Kozlov, R. S., Florescu, I. P., Orasan, R., Trifu, V., Ockenfels, H.-M., Hermes, B., Brockmeyer, N., Dippel, E., Kujath, P., Kowalzick, L., Ulrich, J., Krasnodebski, I., Jaworski, R., Zaniewski, M., Wallner, G., Kapinska-Mrowiecka, M., Dziki, A., Motyka, M., Borschivsky, V. M., Gerych, I. D., Lukashov, S. M., & Pyptyuk, O. V.
Venue
Journal of Antimicrobial Chemotherapy
Published
2010-11-01
Volume
65
Issue
Supplement 4
Pages
iv41-iv51
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W4237533259
Cited by
165
References
3
FWCI
10.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.